BMO Capital Cuts Sarepta Therapeutic (SRPT) PT to $25 from $50

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO Capital adjusted its price target for Sarepta to $25 from $50, while maintaining a Market Perform rating. The decision was made as a response to the temporary pause in Sarepta’s ELEVIDYS program. BMO Capital views this pause as an optimal decision, as refusal to comply with the FDA could lead to regulatory risks across Sarepta’s programs and hinder ELEVIDYS’ uptake.

The temporary halt in ELEVIDYS shipments in the US began at the close of business on July 22 to allow Sarepta and the FDA to complete the safety labeling update process following a patient death linked to acute liver failure and other safety concerns.

In Q1 2025, the company reported total net product revenue of $612 million, representing a 70% growth over the same quarter last year. ELEVIDYS revenue saw a 180% increase year-over-year and reached $375 million. The PMO (peptide-conjugated phosphorodiamidate morpholino oligomer) franchise revenue increased by 5% over the prior year and reached $237 million. Total revenues for the quarter were $745 million, which was an 80% increase year-over-year.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

While we acknowledge the potential of SRPT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.